GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM
GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM
批准号:
2896405
负责人:
JOSEPH M TUSCANO
金额:
$7.4万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-30 至 2001-09-29
关键词:
animal genetic material tag athymic mouse biological signal transduction chronic myelogenous leukemia enzyme activity gene induction /repression genetically modified animals human genetic material tag human tissue neoplasm /cancer genetics neoplastic transformation oncogenes protein kinase receptor tissue /cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Applicant's Description):
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder
of the primitive hematopoietic stem cell. CML accounts for approximately
25% of all adult leukemia. The BCR-ABL oncogene probably represents the
initiating event in nearly all CML, although additional genetic events are
required for the full malignant phenotype. The recently described
serine-threonine kinases GCK and GCKR are known to activate the pathway that
is thought to mediate the transforming ability of BCR-ABL. Specifically,
based on work that is to be presented under Preliminary Studies, the
applicants hypothesize that GCKR specifically associates with, and is
activated by, BCR-ABL and is likely a critical element in BCR-ABL's
transforming potential. Based on this they propose to: 1) examine the
basic elements and requirements that mediate the association between GCKR
and BCR-ABL; 2) examine the functional consequences of the BCR-ABL
relationship with GCKR; 3) assess the in vivo transforming potential of GCK
and GCKR. Elucidating the role of GCKR in BCR-ABL mediated transformation
will allow for a better understanding of the mechanism of oncogenic
transformation, and thus allow for the development of improved treatment and
prognostication strategies for CML. The applicant's training in molecular
biology, immunology, and clinical oncology, in addition to his direct
experience with the initial cloning of GCKR put him in the unique position
to pursue the studies proposed here.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
-
批准号:10421263
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:JOSEPH M TUSCANO
-
依托单位:
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
-
批准号:9779443
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:JOSEPH M TUSCANO
-
依托单位:
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
-
批准号:10057226
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:JOSEPH M TUSCANO
-
依托单位:
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
-
批准号:10616508
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:JOSEPH M TUSCANO
-
依托单位:
CD22-targeted Therapeutics for the Treatment of Lung Cancer
-
批准号:8597910
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:JOSEPH M TUSCANO
-
依托单位:
CD22-targeted Therapeutics for the Treatment of Lung Cancer
-
批准号:8244390
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:JOSEPH M TUSCANO
-
依托单位:
CD22-targeted Therapeutics for the Treatment of Lung Cancer
-
批准号:8764678
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:JOSEPH M TUSCANO
-
依托单位:
PHASE II TRIAL OF BEVACIZUMAB VS BEVACIZUMAB, THALIDOMIDE FOR RELAPSED/REFRACTOR
-
批准号:6975684
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2004
-
负责人:JOSEPH M TUSCANO
-
依托单位:
GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM
-
批准号:6173226
-
项目类别:
-
资助金额:$8.48万
-
财政年份:1998
-
负责人:JOSEPH M TUSCANO
-
依托单位:
GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM
-
批准号:2564624
-
项目类别:
-
资助金额:$7.4万
-
财政年份:1998
-
负责人:JOSEPH M TUSCANO
-
依托单位:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
-
批准号:2058715
-
项目类别:
-
资助金额:$3.02万
-
财政年份:1993
-
负责人:JOSEPH M TUSCANO
-
依托单位:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
-
批准号:3057579
-
项目类别:
-
资助金额:$2.89万
-
财政年份:1992
-
负责人:JOSEPH M TUSCANO
-
依托单位:
海外基金